Compare EFSC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSC | EVO |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 778.3M |
| IPO Year | 1996 | 2007 |
| Metric | EFSC | EVO |
|---|---|---|
| Price | $63.16 | $1.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $66.33 | $7.00 |
| AVG Volume (30 Days) | ★ 162.1K | 41.4K |
| Earning Date | 04-22-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 9.94 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.22 | $1.37 |
| Revenue Next Year | $3.77 | $10.05 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.18 | $1.80 |
| 52 Week High | $68.73 | $4.27 |
| Indicator | EFSC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 38.77 |
| Support Level | $62.48 | N/A |
| Resistance Level | $67.75 | $1.97 |
| Average True Range (ATR) | 0.89 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 23.27 | 16.12 |
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.